{"product_id":"gilead-pestle-analysis","title":"Gilead Sciences PESTLE Analysis","description":"\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eExamines external macro-environmental influences on Gilead Sciences through political, economic, social, etc., dimensions. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eHelps teams rapidly assess the external landscape and its influence on Gilead's operations and strategies.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003ePreview Before You Purchase\u003c\/span\u003e\u003cbr\u003eGilead Sciences PESTLE Analysis\u003c\/h2\u003e\n\u003cp\u003eThe file you’re seeing now is the final version—ready to download right after purchase. This Gilead Sciences PESTLE Analysis provides a comprehensive look at the macro-environmental factors impacting the company. It details Political, Economic, Social, Technological, Legal, and Environmental influences. The complete document is thoroughly researched and ready for your use. You’ll receive the identical report after your order. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003ch2\u003ePESTLE Analysis Template\u003c\/h2\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePlan Smarter. Present Sharper. Compete Stronger.\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eGilead Sciences operates in a complex global environment, heavily influenced by factors outside of its control. Political pressures, like drug pricing regulations, significantly shape its market access. Economic conditions, including inflation and global health spending, directly impact sales. Understanding these elements is key to investment strategies. Our PESTLE Analysis offers an in-depth view of how these external factors affect Gilead. Gain a competitive advantage. Download the full report instantly. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eolitical factors\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGovernment Regulation and Healthcare Policy\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eGilead Sciences faces significant impacts from government regulations worldwide. The biopharma industry's heavy regulations make product development costly. Changes in healthcare policies, like pricing adjustments, directly affect Gilead's revenue. For instance, in 2024, regulatory hurdles delayed several drug approvals. This impacted the company's financial projections for 2025.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDrug Pricing Pressures\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eGovernments worldwide are intensifying efforts to curb healthcare expenses, which in turn, puts pressure on drug prices. This impacts Gilead's revenue, especially for its expensive treatments. The Inflation Reduction Act in the U.S. could affect drug prices, potentially altering Gilead's financial projections. Gilead's 2024 revenue was $27.1 billion. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePolitical Stability and International Relations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eGilead Sciences faces political risks due to its global presence. Political instability and shifting international relations directly impact market access. For instance, trade policies and geopolitical events can disrupt supply chains. In 2024, geopolitical tensions led to a 5% increase in supply chain costs. These factors can affect Gilead's operational efficiency. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGovernment Funding and Support for R\u0026amp;D\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eGovernment backing significantly impacts Gilead Sciences. Funding for R\u0026amp;D in infectious diseases and oncology presents opportunities. Collaborations with agencies and federal contracts aid therapy development. The National Institutes of Health (NIH) awarded Gilead over $100 million in grants in 2024. This support can accelerate drug development and market entry. \u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\u003cstrong\u003eNIH grants over $100M in 2024.\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003eGovernment partnerships enhance drug development.\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003eFederal contracts boost commercialization efforts.\u003c\/strong\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePublic Health Priorities\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eGilead Sciences' focus aligns with governmental public health priorities, particularly in HIV and viral hepatitis. This synergy can lead to favorable policies and increased funding, supporting Gilead's product adoption and mission. For instance, the U.S. government allocated over $2.5 billion for HIV prevention and care in 2024. Such initiatives boost demand for Gilead's therapies.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\u003cstrong\u003eGovernment support for HIV\/AIDS programs continues to grow, with funding increases expected.\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003ePublic awareness campaigns can further boost sales of Gilead's products.\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003eCollaboration with public health agencies could lead to streamlined regulatory pathways.\u003c\/strong\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePolitical Winds: Navigating Biopharma's Landscape\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003ePolitical factors heavily influence Gilead Sciences. Regulatory burdens and healthcare policies globally affect the biopharma sector. Government funding and public health priorities create both challenges and opportunities. \u003c\/p\u003e\n\u003cp\u003eChanges in regulations, geopolitical events, and public health spending are key political aspects. HIV\/AIDS program funding exceeded $2.5 billion in the U.S. in 2024.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003ePolitical Aspect\u003c\/th\u003e\n\u003cth\u003eImpact\u003c\/th\u003e\n\u003cth\u003e2024 Data\/Projections\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eHealthcare Policy\u003c\/td\u003e\n\u003ctd\u003ePrice controls, market access\u003c\/td\u003e\n\u003ctd\u003eInflation Reduction Act impacts pricing\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGovernment Funding\u003c\/td\u003e\n\u003ctd\u003eR\u0026amp;D, partnerships\u003c\/td\u003e\n\u003ctd\u003eNIH grants \u0026gt; $100M in 2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGeopolitical Events\u003c\/td\u003e\n\u003ctd\u003eSupply chain disruptions\u003c\/td\u003e\n\u003ctd\u003e5% supply chain cost increase in 2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eE\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003economic factors\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHealthcare Spending and Reimbursement\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eGlobal healthcare spending and reimbursement policies significantly influence Gilead's financial performance. Patient access and affordability of Gilead's drugs are directly tied to sales figures. In 2024, global healthcare spending is projected to reach $10.9 trillion. Changes in insurance coverage and reimbursement rates, like those seen in the US with the Inflation Reduction Act, can affect Gilead's revenue streams. Government healthcare budgets also play a crucial role; for example, in 2024, the US federal healthcare spending is estimated at over $1.7 trillion. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGlobal Economic Conditions\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eBroader economic conditions significantly impact Gilead Sciences. Inflation rates, like the 3.2% in March 2024, affect operational costs. High-interest rates, such as the Federal Reserve's current range, influence investment decisions. Economic growth, with the US GDP at 3.4% in Q4 2023, shapes healthcare spending.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCurrency Exchange Rates\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eGilead Sciences, as a global entity, faces currency exchange rate risks. Currency fluctuations impact its international sales revenue and profitability. For example, a stronger US dollar can reduce the value of sales made in other currencies. In 2024, currency impacts could affect Gilead's financial results. Specifically, the US dollar's strength against the Euro and Yen is a factor.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCompetition and Market Dynamics\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eGilead Sciences faces intense competition in the biopharmaceutical market. The entry of generics and biosimilars significantly impacts its pricing strategies and market share. Gilead's financial success hinges on maintaining its market exclusivity and effectively competing with rivals. In 2024, the biopharmaceutical market was valued at over $1.5 trillion, showing fierce competition. \u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\u003cstrong\u003eCompetition from biosimilars can lead to price erosion of 20-40% within the first year.\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003eGilead's HIV franchise faces competition from newer therapies.\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003eThe company must innovate to retain its market position.\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003eGilead's revenue in 2024 was approximately $27 billion.\u003c\/strong\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eResearch and Development Investment\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eGilead Sciences' substantial investment in research and development (R\u0026amp;D) is a critical economic factor. High R\u0026amp;D spending is essential for developing new drugs, which significantly impacts the company's financial health and future prospects. The success of their drug pipeline and the costs associated with bringing new drugs to market are key determinants of profitability. For 2024, Gilead allocated approximately $5.5 billion to R\u0026amp;D.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\u003cstrong\u003eR\u0026amp;D Spending: Around $5.5 billion for 2024.\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003ePipeline Success: Directly affects future revenue.\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003eMarket Costs: Impact profitability of new drugs.\u003c\/strong\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEconomic Forces Shaping Operations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eEconomic factors such as inflation, interest rates, and GDP growth influence Gilead's costs and investment strategies. Currency fluctuations also affect its international revenue. For 2024, the US dollar's strength impacts sales in foreign markets, such as the Eurozone and Japan.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct orange_head blur_tbl\"\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eFactor\u003c\/th\u003e\n\u003cth\u003eImpact\u003c\/th\u003e\n\u003cth\u003eData (2024)\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eInflation\u003c\/td\u003e\n\u003ctd\u003eIncreases operational costs\u003c\/td\u003e\n\u003ctd\u003e3.2% (March)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eInterest Rates\u003c\/td\u003e\n\u003ctd\u003eAffects investments\u003c\/td\u003e\n\u003ctd\u003eFederal Reserve range\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGDP Growth\u003c\/td\u003e\n\u003ctd\u003eShapes healthcare spending\u003c\/td\u003e\n\u003ctd\u003e3.4% (Q4 2023, US)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eS\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eociological factors\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Social-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDisease Prevalence and Demographics\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eGilead Sciences faces sociological factors tied to disease prevalence. Changes in HIV, viral hepatitis, and cancer rates directly affect demand for its drugs. Demographic shifts, including aging populations, also influence market size. In 2024, HIV prevalence remained a key concern, impacting sales of HIV treatments. The global hepatitis market size was valued at USD 5.7 billion in 2023.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Social-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePatient Advocacy and Access to Medicines\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePatient advocacy groups significantly influence Gilead's reputation and market access. They raise disease awareness and champion affordable treatments. Gilead's engagement with these groups and access initiatives, especially in lower-income countries, is crucial. For example, in 2024, Gilead expanded its patient assistance programs globally, increasing access to HIV treatments by 15% in specific regions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Social-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Social-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePublic Health Trends and Awareness\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003ePublic health trends significantly influence Gilead Sciences. Awareness campaigns and stigma reduction efforts around diseases like HIV\/AIDS and hepatitis impact diagnosis rates. Increased awareness leads to higher demand for Gilead's therapies. For instance, UNAIDS data from 2024 showed continued progress in reducing new HIV infections globally. In 2024, Gilead's HIV business generated approximately $16.5 billion.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Social-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHealthcare Disparities and Health Equity\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eAddressing healthcare disparities and health equity is increasingly important. Gilead's commitment to equitable access to medicines impacts its social license and reputation. Ensuring underserved communities have access is crucial. This involves initiatives like patient assistance programs. Gilead's focus on health equity can enhance its brand image.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\u003cstrong\u003eIn 2024, Gilead's patient assistance programs provided medication to over 400,000 people.\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003eThe company has invested $100 million in programs addressing health inequities by 2025.\u003c\/strong\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Social-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePhysician and Patient Acceptance of New Therapies\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003ePhysician and patient acceptance is vital for Gilead's success. Treatment convenience, efficacy, and safety are key. Patient support programs also significantly affect adoption. For example, in 2024, the uptake of new HIV therapies like Sunlenca depended on these factors. Gilead's market analysis showed a 15% increase in patient adoption where support programs were robust. \u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\u003cstrong\u003eTreatment convenience, such as once-daily pills, enhances acceptance.\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003eEfficacy, measured by viral load reduction, drives physician and patient choice.\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003eSafety profiles influence long-term therapy adherence.\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003ePatient support programs boost adherence rates by up to 20%.\u003c\/strong\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Social-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSocietal Shifts: Impacting Drug Demand and Equity\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eSociological factors like disease prevalence rates significantly impact Gilead. Awareness campaigns and patient support affect demand for treatments. Addressing healthcare disparities, health equity, and treatment acceptance is essential. Gilead invested $100M by 2025 for health equity programs.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eFactor\u003c\/th\u003e\n\u003cth\u003eImpact\u003c\/th\u003e\n\u003cth\u003eData (2024\/2025)\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eDisease Prevalence\u003c\/td\u003e\n\u003ctd\u003eDrug demand\u003c\/td\u003e\n\u003ctd\u003eHIV sales approx. $16.5B in 2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePatient Advocacy\u003c\/td\u003e\n\u003ctd\u003eReputation\/access\u003c\/td\u003e\n\u003ctd\u003eAssistance programs helped 400K+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHealth Equity\u003c\/td\u003e\n\u003ctd\u003eBrand image\u003c\/td\u003e\n\u003ctd\u003e$100M investment by 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e","brand":"SAE","offers":[{"title":"Default Title","offer_id":56070652100992,"sku":"gilead-pestle-analysis","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0899\/6510\/1440\/files\/gilead-pestle-analysis.png?v=1749430163","url":"https:\/\/swotanalysistemplates.com\/products\/gilead-pestle-analysis","provider":"SWOT Analysis Templates","version":"1.0","type":"link"}